2. Jason Barr – Team Leader Sharon Valvona – Main Client Contact Marina Stavrakantonaki – Main Customer Contact Scott Junkin – Technology Specialist Andy Dickson – Mentor Michael Sapienza – Mentor

3. “…died of massive uncontrolled and untreated bleeding as a result of the clips' having moved out of place. “ “Haaretz”, December 2006 “a wayward spark… seared a tiny hole in her colon… malfunctioning bladder and disabling pain… 13 operations so far…prevent her from working or bearing children” New York Times, March 2006

4. " It wouldn't surprise me in the least if it caused more than 100 deaths and 10,000 injuries annually," Dr. Alan Johns " Very little has changed since the first minimally- invasive surgeries in the early 1990s. The tools we use are still remarkably crude." Dr. Wayne Poll Between 1996 and 2005, 27 adverse events have been reported 2 resulted in death - due to delayed postoperative bleeding. clips apparently had been placed without issue did not maintain control of the vessel. “ Reported Failures Of The Polymer Self-Locking (Hem-O-Lok) Clip” Urology / NephrologyUrology / Nephrology Feb 2007

5. Self-Articulating Coil Technology Features Compression Member –Outer surface –Hollow –Compressed under tension at designated areas Tensioning Member –Inner material –Moves within compression member Retainment member –Stops movement of tensioning member –Provides force transfer to compression members Retaining Member Compression Member Tensioning Member

6. Solution

7. Market Opportunity $10.6 Billion 3.7% = $389Million

8. Unique Competitive Advantage Simplicity Flexibility Size Operable in a Single Plane Benignancy

9. Competition Medtronic Boston Scientific Johnson & Johnson St. Jude Medical Simplex Annual Sales ($ mil.) 12,299.007,821.0053,324.003,779.30389.00 Employees 38,00028,600122,20012,000250 Market Cap ($ mil.) 54,678.7018,760.10177,883.2014,972.1010X?

10. From now until beginning of 2009 Get the Product to the Market 2009 – 2010 Prove Value in Live Surgery 2010 – 2011 Build Reputation of Excellence 2011 – 2015 Exit thru Sale FDA Approval Market Entry Tactical Success Strategic Success Market Penetration

11. Financials (000’s)2009201020112012201320142015 Revenues4,2849,08419,26040,83986,592183,603389,296 Operating Expenses 6,3488,51015,40629,32956,255111,758224,843 Net Income(2,064)3432,3126,90518,20243,10698,671 Cumulative Cash Flow (5,303)(5,383)(3,695)2,10318,07056,549145,622 Investment5,400 Total Investment Required to Breakeven

12. The Team Andy Dickson, Executive Mentor  16 years of professional experience as an investment professional.  Co-founder of a frim that helps early-stage companies successfully raise private equity. Scott Junkin  Sr. Product Engineer, Emerson Eric Foster  MS Engineering Advisory Board  TBD

13. Short-term Goals Product validation Surgeon champions IP negotiation Early stage funding Trial prototype FDA 510K exemption

14. Extra Slides Formats if Needed